VRNA Verona Pharma: Business Value to Revenue

Public company logo of Verona Pharma PLC (VRNA)

Verona Pharma plc (VRNA) is implementing advanced respiratory therapy methods, creating unique drug classes. Stable demand for such medications minimizes the impact of economic crises, while strict control over raw material supplies eliminates logistical disruptions. This chart in the GURU.Markets terminal illustrates the EV/Sales history, where the value has settled at , signaling a potential overheating of the asset's valuation relative to revenue.

veronapharma.com (VRNA): Enterprise Value-to-Revenue Ratio from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for Verona Pharma Corp (VRNA)

- price and consensus price forecast:
Initial company analysis:Verona Pharma plc
Mass-produced product of Verona Pharma PLC

Institutional capital utilizes this metric to determine asset overbought conditions through the lens of its actual market value. The EV-to-revenue ratio for the company compares the total enterprise value, adjusted for net debt, against sales volume to reveal capitalization efficiency. For Verona Pharma plc (VRNA), this indicator reflects market expectations regarding the implementation of eco-friendly inhalers, confirming the fundamental resilience of the biopharmaceutical business.

Competitor analysis for Verona Pharma plc

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Jyong Biotech Limited (MENS)|LGND (Ligand Pharmaceuticals Incorporated) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amneal Pharmaceuticals Inc AMRX|EV/Sales Multiple PRGO|Enterprise Value-to-Revenue Coefficient ALVO|EV/Sales Multiple LQDA (Liquidia Technologies)|EV/Sales Multiple Galapagos GLPG|ANI Pharmaceuticals Inc - EV/Sales Multiple|MNKD (MannKind Corp.) - Company Value to Revenue Ratio|AMPH: EV/Sales Multiple|PCRX (Pacira BioSciences) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ARS Pharmaceuticals Inc|Company Value to Revenue Theravance Biopharma, Inc. (TBPH)|Company Value to Revenue AQST (Aquestive Pharma)|SCPH - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio